Table 2. Evolution of patients' characteristics and outcome during the study period.
| 2002-2003 (n=77) | 2004-2005 (n=108) | 2006-2007 (n=61) | 2008-2009 (n=83) | 2010-2011 (n=89) | p Value | |
|---|---|---|---|---|---|---|
| Agea | 53 ± 14 | 54 ± 15 | 57 ± 14 | 55 ± 17 | 57 ± 17 | 0.16 |
| Sex (male)b | 40 (52) | 65 (60) | 38 (62) | 47 (57) | 54 (61) | 0.52 |
| Hematological malignanciesb | ||||||
| Acute leukemia | 35 (45) | 72 (67) | 33 (58) | 51 (61) | 48 (54) | 0.11 |
| Myeloma | 17 (22) | 18 (17) | 10 (16) | 15 (18) | 9 (10) | 0.33 |
| Lymphoma | 12 (16) | 12 (11) | 6 (10) | 7 (8) | 16 (18) | 0.31 |
| Treatment/Conditionb | ||||||
| Allogeneic HSCT | 20 (26) | 32 (30) | 19 (31) | 20 (24) | 25 (28) | 0.81 |
| Neutropenia | 20 (26) | 33 (31) | 16 (26) | 29 (35) | 26 (29) | 0.79 |
| IMVc | 38 (49) | 56 (52) | 25 (41) | 36 (43) | 41 (46) | 0.87 |
| SAPS IIa | 52 ± 22 | 58 ± 25 | 57 ± 14 | 61 ± 26 | 59 ± 20 | 0.24 |
| Day-28 mortalityb | 37 (48) | 59 (55) | 26 (43) | 42 (51) | 39 (44) | 0.75 |
| Day-90 mortalityb | 43 (56) | 67 (62) | 32 (52) | 49 (59) | 51 (57) | 0.43 |
| 1-year mortalityb | 53 (69) | 82 (76) | 41 (67) | 60 (72) | 66 (74) | 0.96 |
a
Data expressed as mean ± SD.
b
Data expressed as number (percentage).
c
Within the first 48 hours
HSCT: hematopoietic stem cell transplantation; IMV: invasive mechanical ventilation; SAPS II: simplified acute physiology score II.